Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/13/2017 | 03:31pm CEST

TOKYO, Oct. 13 -- Eisai issued the following news release:

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), Toyama Chemical Co., Ltd. of the Fujifilm Group (Headquarters: Tokyo, President: Junji Okada, "Toyama Chemical") and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chief Executive Officer: Shigeru Uehara, "Taisho Pharmaceutical") announced today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET (R) Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Kenichi Fujita, "TaishoToyama").

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.

Iguratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying Anti- Rheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram (R) Tablets 25 mg and KOLBET (R) Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.

Targeted News Service, source News Service

Stocks mentioned in the article
ChangeLast1st jan.
FUJIFILM HOLDINGS CORP -1.56% 4215 End-of-day quote.-10.43%
TAISHO PHARMACEUTICAL INDONESIA TBK PT --End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
06/15EISAI : To establish new research facility 'eisai center for genetics guided dem..
AQ
06/15EISAI : Industry-academia-government joint development agreement concerning nucl..
AQ
06/15EISAI : to set up dementia research facility in US
AQ
06/14EISAI : Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerabi..
AQ
06/14EISAI : to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Ma..
AQ
06/14EISAI : Industry-Academia-Government Joint Development Agreement Concerning Nucl..
AQ
06/14EISAI : looking past amyloid, tau with new drug discovery center
AQ
06/14EISAI : to close Andover site, move to new Alzheimers drug discovery center in C..
AQ
06/14EISAI : Industry-Academia-Government Joint Development Agreement Concerning Nucl..
AQ
06/13EISAI : to Establish New Research Facility 'Eisai Center for Genetics Guided Dem..
AQ
More news
News from SeekingAlpha
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
06/07This One Study Could Radically Change The Cancer Immunotherapy Market 
06/05Eisai and Biogen's elenbecestat shows encouraging action in mid-stage Alzheim.. 
06/05MINING ASCO 2018'S GOLD, PART 11 : The Pains In The Neck 
06/01MINING ASCO 2018'S GOLD, PART 8 : Angiogenesis Taking Back Control Of Liver Canc.. 
Financials ( JPY)
Sales 2019 625 B
EBIT 2019 85 000 M
Net income 2019 52 714 M
Finance 2019 91 406 M
Yield 2019 1,85%
P/E ratio 2019 41,85
P/E ratio 2020 43,80
EV / Sales 2019 3,73x
EV / Sales 2020 3,72x
Capitalization 2 424 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 7 591  JPY
Spread / Average Target -6,2%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD22.90%22 098
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880